Wistuba, I. I., Kalra, M., Backert, L., Wermke, M., Parra, E. R., Luke, J. J., . . . Krishna, D. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. BMJ Publishing Group.
Chicago Style (17th ed.) CitationWistuba, Ignacio I., et al. First-in-human Dose Escalation Trial to Evaluate the Clinical Safety and Efficacy of an Anti-MAGEA1 Autologous TCR-transgenic T Cell Therapy in Relapsed and Refractory Solid Tumors. BMJ Publishing Group.
MLA (9th ed.) CitationWistuba, Ignacio I., et al. First-in-human Dose Escalation Trial to Evaluate the Clinical Safety and Efficacy of an Anti-MAGEA1 Autologous TCR-transgenic T Cell Therapy in Relapsed and Refractory Solid Tumors. BMJ Publishing Group.